New depression pill shows promise in Late-Stage trial
NCT ID NCT06941844
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This phase 3 study tests an oral medication called MM120 against a placebo in 149 adults with major depressive disorder. Participants take the drug or placebo for 12 weeks, followed by a 40-week period where everyone can receive MM120. The main goal is to see if MM120 reduces depression symptoms more than placebo, measured by a standard depression rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adams Clinical
Watertown, Massachusetts, 02472, United States
-
Adams Clinical Boston
Boston, Massachusetts, 02116, United States
-
Adams Clinical Harlem
New York, New York, 10029, United States
-
Adams Clinical Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Austin Clinical Trial Partners
Austin, Texas, 78737, United States
-
Cedar Clinical Research
Murray, Utah, 84020, United States
-
Cenexel HRI
Berlin, New Jersey, 08053, United States
-
Charter Research
Orlando, Florida, 32803, United States
-
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida, 32256, United States
-
Clinical Neuroscience Solutions, Inc
Orlando, Florida, 32801, United States
-
Clinical Neuroscience Solutions, Inc
Memphis, Tennessee, 38119, United States
-
Columbia - New York State Psychiatric Institute
New York, New York, 10032, United States
-
Dell Medical School, University of Texas at Austin
Austin, Texas, 78712, United States
-
FutureSearch Trials of Dallas
Dallas, Texas, 75231, United States
-
Kadima Neuropsychiatry Institute
La Jolla, California, 92037, United States
-
Memory Clinic, Inc
Bennington, Vermont, 05201, United States
-
Mountain View Clinical Research, Inc
Denver, Colorado, 80209, United States
-
Neuro-Behavioral Clinical Research
Canton, Ohio, 44720, United States
-
Preferred Research Partner
Fayetteville, Arkansas, 72703, United States
-
Preferred Research Partners, Inc
Little Rock, Arkansas, 72211, United States
-
Psychedelic Science Institute
Santa Monica, California, 90404, United States
-
Sheppard Pratt
Baltimore, Maryland, 21204, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Missouri
Columbia, Missouri, 65212, United States
-
Uptown Research
Chicago, Illinois, 60640, United States
Conditions
Explore the condition pages connected to this study.